In a mouse model of Marfan syndrome, which is characterised by elevated TGFβ activity due to LOF mutations in fibrillin-1, IL11 levels are increased and anti-IL11 therapy reduces aortic inflammation, matrix remodelling and dilatation [178]. This evidence concerns the gene TGFB1 and Marfan syndrome.